



ASX ANNOUNCEMENT

28 August 2023

Late lodgement of Appendix 3Y

Attached is an Appendix 3Y – Change of Director’s Interest Notice for Paul Hopper.

The Company considers the late lodgement as an isolated incident which arose due to the proximity of the placement and share purchase plan of which Mr Paul Hopper participated in both. The results of the placement and share purchase plan were announced on 23 June 2023. The Company believes that its current practices are adequate to ensure compliance with the Corporations Act and ASX Listing Rules, however, it is exploring additional compliance monitoring with the share registry.

The Company and the Directors are aware of their obligations under the Corporations Act and ASX Listing Rules 3.19A and 3.19B to provide the necessary information to the Company to meet its disclosure requirements.

Phillip Hains
Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	17 July 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	23 June 2023														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>375,000</td><td>-</td></tr><tr><td>Indirect</td><td>93,762,432</td><td>2,941,176</td></tr><tr><td>Total</td><td>94,137,432</td><td>2,941,176</td></tr></table>				Shares	Options	Direct	375,000	-	Indirect	93,762,432	2,941,176	Total	94,137,432	2,941,176
	Shares	Options													
Direct	375,000	-													
Indirect	93,762,432	2,941,176													
Total	94,137,432	2,941,176													
Class	Fully Paid Ordinary Shares														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>857,142</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>857,142</td><td>-</td></tr></table>				Shares	Options	Direct	857,142	-	Indirect	-	-	Total	857,142	-
	Shares	Options													
Direct	857,142	-													
Indirect	-	-													
Total	857,142	-													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.035 per share per SPP		
No. of securities held after change		Shares	Options
	Direct	1,232,142	-
	Indirect	93,762,432	2,941,176
	Total	94,994,574	2,941,176
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in SPP announced on 15 May 2023.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

+ See chapter 19 for defined terms.